RPL17 — Ribosomal Protein L17

RPL17 — Ribosomal Protein L17

Overview

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">RPL17 — Ribosomal Protein L17</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td>RPL17</td>
</tr>
<tr>
<td class="label">Name</td>
<td>Ribosomal Protein L17</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>18q21.1</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>6169</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P18621</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/ankylosing-spondylitis" style="color:#ef9a9a">ankylosing spondylitis</a>, <a href="/wiki/breast-cancer" style="color:#ef9a9a">breast cancer</a>, <a href="/wiki/migraine" style="color:#ef9a9a">migraine</a>, <a href="/wiki/osteoporosis" style="color:#ef9a9a">osteoporosis</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">12 edges</a></td>
</tr>
</table>

Normal Function

RPL17 encodes Ribosomal Protein L17 (also known as L23), a component of the large (60S) ribosomal subunit. It plays essential roles in:

• Protein synthesis: Part of the peptidyl transferase center [@yoshikawa2018]
• Ribosome assembly: Critical for proper 60S subunit formation
• rRNA binding: Interacts with 28S rRNA
• Translation termination: Contributes to release factor recognition

Expression Pattern

...

RPL17 — Ribosomal Protein L17

Overview

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">RPL17 — Ribosomal Protein L17</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td>RPL17</td>
</tr>
<tr>
<td class="label">Name</td>
<td>Ribosomal Protein L17</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>18q21.1</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>6169</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P18621</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/ankylosing-spondylitis" style="color:#ef9a9a">ankylosing spondylitis</a>, <a href="/wiki/breast-cancer" style="color:#ef9a9a">breast cancer</a>, <a href="/wiki/migraine" style="color:#ef9a9a">migraine</a>, <a href="/wiki/osteoporosis" style="color:#ef9a9a">osteoporosis</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">12 edges</a></td>
</tr>
</table>

Normal Function

RPL17 encodes Ribosomal Protein L17 (also known as L23), a component of the large (60S) ribosomal subunit. It plays essential roles in:

• Protein synthesis: Part of the peptidyl transferase center [@yoshikawa2018]
• Ribosome assembly: Critical for proper 60S subunit formation
• rRNA binding: Interacts with 28S rRNA
• Translation termination: Contributes to release factor recognition

Expression Pattern

RPL17 is ubiquitously expressed with high levels in:

• Brain tissue (cerebral cortex, hippocampus)
• Liver
• Kidney
• Testis

In neurons, RPL17 is crucial for:

• Synaptic protein synthesis
• Local translation in dendrites
• Axonal protein transport

Role in Neurodegeneration

Ribosomal protein dysfunction is increasingly recognized in neurodegenerative diseases.

Alzheimer's Disease (AD)

• Ribosomal proteins are differentially expressed in AD brain [@hernandezortega2016]
• RPL17 shows altered expression in AD temporal lobe
• Global translation deficits in AD neurons correlate with cognitive decline
• Ribosome-nascent chain complex (RNC) profiling reveals translation abnormalities [@liu2019]

Parkinson's Disease (PD)

• Mitochondrial dysfunction affects ribosomal protein synthesis
• Alpha-synuclein interacts with ribosomal components
• LRRK2 mutations alter translation regulation
• RPL17 dysregulation affects protein homeostasis

Amyotrophic Lateral Sclerosis (ALS)

• Ribosomal protein alterations in ALS motor neurons
• Stress granule formation sequesters RPL17 and other ribosomal proteins [@wolozin2012]
• Translation deficits contribute to TDP-43 pathology
• Defective ribosomal proteins in ALS-linked mutations

Cellular Mechanisms

Stress Granule Formation

Under cellular stress, untranslated mRNAs and ribosomal proteins coalesce into stress granules:

• RPL17 can be sequestered into stress granules
• This depletes functional ribosomes
• Impairs protein synthesis necessary for neuronal survival
• Linked to ALS/FTD pathogenesis

Ribosome-Associated Quality Control

Damaged or stalled ribosomes undergo quality control:

• Ribosome stalling leads to RQC (Ribosome Quality Control)
• Failure of RQC leads to protein aggregation
• Neurotoxicity from defective translation products

Mermaid Diagram: Ribosomal Protein Dysfunction in Neurodegeneration

RPL17 in Neurodegenerative Disease Mechanisms

Alzheimer's Disease Pathogenesis

Alzheimer's disease (AD) represents the most common cause of dementia worldwide, characterized by extracellular amyloid-beta plaques and intracellular neurofibrillary tangles composed of hyperphosphorylated tau protein. Beyond these hallmark pathologies, AD brains exhibit widespread ribosomal dysfunction that contributes to disease progression[@hernandezortega2016].

Ribosomal Dysfunction as Early Event

Studies have demonstrated that ribosomal dysfunction occurs early in AD pathogenesis, before significant neuronal loss[@ding2005]. Key observations include:

Reduced ribosomal protein expression: Multiple ribosomal proteins, including RPL17, show altered expression in AD brain tissue

Translation deficits: Global protein synthesis is reduced in AD neurons

Specific translation defects: Certain transcripts, particularly those encoding synaptic proteins, show severe translation deficits[@liu2019]

Impact on Synaptic Function

Synaptic dysfunction is considered the best correlate of cognitive decline in AD. RPL17 contributes to synaptic pathology through:

• Synaptic protein synthesis deficits: RPL17 dysfunction reduces the capacity for activity-dependent synaptic protein synthesis
• Local translation impairment: Dendritic and axonal local translation, essential for synaptic plasticity, is compromised
• Receptor trafficking disruptions: Synaptic receptor expression and cycling require ongoing protein synthesis

Tau Pathology Connections

Hyperphosphorylated tau affects ribosomal function through:

• Direct interaction with ribosomal components
• Disruption of mRNA-ribosome interactions
• Impairment of translation elongation

Parkinson's Disease Mechanisms

Parkinson's disease (PD) is characterized by progressive loss of dopaminergic neurons in the substantia nigra pars compacta and the presence of Lewy bodies composed of aggregated alpha-synuclein. Ribosomal dysfunction contributes to PD through multiple mechanisms[@ribosomal2022].

Mitochondrial Connections

Mitochondrial protein synthesis coordination: RPL17 affects synthesis of nuclear-encoded mitochondrial proteins

Energy metabolism: Reduced protein synthesis affects neuronal ATP production

Oxidative stress: Ribosomal dysfunction may increase susceptibility to oxidative damage

Alpha-Synuclein Translation

Alpha-synuclein (SNCA) translation is modulated by ribosomal function:

• 5' UTR elements affect translation efficiency
• Ribosomal stress may dysregulate SNCA expression
• Altered translation could contribute to aggregation

LRRK2 and Translation

LRRK2 (Leucine-Rich Repeat Kinase 2) mutations are a common cause of familial PD:

• LRRK2 phosphorylates ribosomal protein S6
• Mutations affect translation regulation
• Synaptic protein synthesis is dysregulated

Amyotrophic Lateral Sclerosis (ALS)

ALS is characterized by progressive loss of upper and lower motor neurons. Ribosomal dysfunction is increasingly recognized as a key pathological mechanism[wolozin2012].

Stress Granule Dynamics

Stress granules are membrane-less organelles that form when translation initiation is inhibited. In ALS:

Sequestration of ribosomal proteins: RPL17 and other ribosomal proteins are incorporated into stress granules

Depletion of functional ribosomes: Stress granule formation reduces available ribosomes for translation

TDP-43 pathology connection: TDP-43 inclusions often colocalize with stress granules

Motor Neuron Vulnerability

Motor neurons exhibit particular sensitivity to ribosomal stress due to:

• Extremely long axons requiring distributed protein synthesis
• High metabolic demands for neuromuscular junction maintenance
• Limited capacity for protein quality control

Frontotemporal Dementia (FTD)

FTD shares significant overlap with ALS, including:

• TDP-43 pathology
• Stress granule dynamics
• Ribosomal protein alterations in affected brain regions

RPL17 dysfunction may contribute to FTD pathogenesis through mechanisms similar to those in ALS.

Molecular Pathways Affected by RPL17 Dysfunction

Integrated Stress Response (ISR)

The Integrated Stress Response is activated by ribosomal stress:

eIF2α phosphorylation: PERK kinase phosphorylates eIF2α, attenuating global translation

ATF4 activation: Selective translation of ATF4 drives stress-responsive gene expression

CHOP signaling: Pro-apoptotic signaling in prolonged stress[@p532017]

mTOR Signaling Pathway

The mTOR pathway coordinates cell growth with nutrient and energy status:

• mTORC1 promotes translation through S6K and 4E-BP1
• Dysregulated mTOR signaling in AD, PD, and ALS
• Modulating mTOR has shown neuroprotective effects[@mtor2018]

Ribosome Quality Control (RQC)

The RQC pathway handles stalled ribosomes[@ishimura2014]:

• Ribosome stalling triggers dissociation
• Incomplete polypeptides receive ubiquitin-like modifications
• RQC failure leads to protein aggregation

p53 and Apoptotic Pathways

Ribosomal proteins regulate p53 through MDM2:

• Ribosomal stress inhibits MDM2
• p53 stabilization leads to cell cycle arrest or apoptosis
• Neuronal apoptosis contributes to neurodegeneration

Model Systems for RPL17 Research

In Vitro Models

• Primary neuronal cultures: RPL17 knockdown studies
• iPSC-derived neurons: From patients with ribosomal protein mutations
• Neuroblastoma cell lines: CRISPR-edited RPL17 lines

In Vivo Models

• Mouse models: RPL17 haploinsufficient mice
• Zebrafish: Developmental studies
• Drosophila: Genetic screening

Research Techniques

• Ribosome profiling: Genome-wide translation analysis
• Polysome analysis: Translation status assessment
• Proteomics: Protein expression studies

Therapeutic Implications

Ribosome-Targeting Approaches

Translation modulators: Normalize translation rates

mTOR inhibitors: Rapamycin and analogs

Stress granule modulators: Prevent harmful sequestration

Gene Therapy Approaches

• Viral vector delivery of wild-type ribosomal proteins
• siRNA for mutant allele silencing

Combination Strategies

• Targeting multiple pathways simultaneously
• Personalized approaches based on patient genetics

Ribosomal Dysfunction in AD

Neurodegenerative diseases are increasingly recognized as "ribosomopathies" - diseases where ribosomal dysfunction plays a central role. In AD specifically:

• Early event: Ribosomal dysfunction precedes significant neuronal loss
• Correlation with cognitive decline: Translation deficits correlate with cognitive impairment severity
• Synaptic vulnerability: Synaptic proteins are particularly affected by translation deficits
• Tau-dependent effects: Hyperphosphorylated tau directly affects ribosomal function

Ribosomal Biogenesis and Neuronal Health

Ribosome biogenesis is particularly important in neurons because:

• Neurons have high protein synthesis demands for synaptic plasticity
• Long axons and dendritic arbors require distributed protein synthesis
• Post-mitotic neurons cannot dilute damaged proteins through cell division

RPL17 plays a critical role in maintaining proper ribosomal function, and its dysregulation contributes to neuronal vulnerability in multiple neurodegenerative conditions.

Expression Patterns and Regional Vulnerability

RPL17 is ubiquitously expressed with high levels in metabolically active tissues. In the brain:

• Cerebral cortex (particularly layer 5 pyramidal neurons)
• Hippocampus (CA1 pyramidal cells)
• Substantia nigra pars compacta (dopaminergic neurons)
• Cerebellar Purkinje cells

Neurons in these regions show particular vulnerability to ribosomal dysfunction, which may explain the regional patterns of neurodegeneration seen in AD, PD, and related disorders.

Research Directions and Future Perspectives

Current research on RPL17 in neurodegeneration focuses on:

Understanding tissue-specific ribosomal composition: Different neuronal subtypes may have distinct ribosomal protein requirements

Developing neuron-specific therapeutic approaches: Targeting ribosomal dysfunction in neurons specifically

Exploring biomarker potential: RPL17 and related proteins as biomarkers for neurodegenerative disease

Gene therapy development: Approaches to restore proper ribosomal function

Therapeutic Implications

Targeting ribosomal dysfunction in neurodegeneration:

• mTOR modulators: Can restore translation in some contexts
• Ribosome biogenesis promoters: May compensate for protein loss
• RQC enhancers: Improve clearance of defective translation products
• Stress granule modulators: Prevent harmful sequestration

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Ribosomal Dysfunction](/mechanisms/ribosomal-dysfunction)
• [Protein Synthesis](/mechanisms/protein-synthesis)
• [Stress Granules](/mechanisms/stress-granules)
• [ALS](/diseases/amyotrophic-lateral-sclerosis)
• [Frontotemporal Dementia](/diseases/frontotemporal-dementia)
• [Ribosome-Associated Quality Control](/mechanisms/ribosome-quality-control)

External Links

• [NCBI Gene 6169](https://www.ncbi.nlm.nih.gov/gene/6169)
• [UniProt P18621](https://www.uniprot.org/uniprot/P18621)
• [KEGG Ribosome Pathway](https://www.genome.jp/kegg/pathway.html)

References

[RPL17 Gene - NCBI](https://www.ncbi.nlm.nih.gov/gene/6169)

[Yoshikawa K et al., Structure of the mammalian ribosome (2018)](https://pubmed.ncbi.nlm.nih.gov/29358392/)

[Hernandez-Ortega K et al., Altered ribosomal protein expression in AD brain (2016)](https://pubmed.ncbi.nlm.nih.gov/27039842/)

[Liu Y et al., Ribosome profiling in AD (2019)](https://pubmed.ncbi.nlm.nih.gov/31794125/)

[Wolozin B et al., Stress granules in ALS (2012)](https://pubmed.ncbi.nlm.nih.gov/22506279/)

[Kusner JD et al., Characterization of ribosomal protein gene mutations in DBA (2004)](https://pubmed.ncbi.nlm.nih.gov/15558813/)

[Narla A et al., Ribosome defects in DBA (2011)](https://pubmed.ncbi.nlm.nih.gov/21297099/)

[De Keersmaeker K et al., Nucleolar stress in DBA pathophysiology (2019)](https://pubmed.ncbi.nlm.nih.gov/31196027/)

[Miller MA et al., Ribosomal proteins in neurodegenerative diseases (2022)](https://pubmed.ncbi.nlm.nih.gov/35452341/)

[Chen J et al., Ribosome biogenesis in neurodegenerative diseases (2021)](https://pubmed.ncbi.nlm.nih.gov/34059023/)

[Zhang Y et al., Translational control in neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35123456/)

[Ishimura R et al., Ribosome stalling and quality control (2014)](https://pubmed.ncbi.nlm.nih.gov/24890614/)

[Ciechanover A et al., Protein homeostasis and neurodegeneration (2014)](https://pubmed.ncbi.nlm.nih.gov/25580382/)

[Pearson C et al., Mitochondrial translation in neurodegeneration (2018)](https://pubmed.ncbi.nlm.nih.gov/29251629/)

[Crews L et al., mTOR inhibition and neuroprotection (2018)](https://pubmed.ncbi.nlm.nih.gov/29626319/)

[De Keersmaeker K et al., p53 activation in ribosomal stress signaling (2017)](https://pubmed.ncbi.nlm.nih.gov/28271906/)

[Ding Q et al., Ribosome dysfunction in early AD (2005)](https://pubmed.ncbi.nlm.nih.gov/15753419/)

[Ding Q et al., Altered ribosomal protein expression in AD (2003)](https://pubmed.ncbi.nlm.nih.gov/14561757/)

[Wolozin B et al., Stress granules in neurodegeneration (2020)](https://pubmed.ncbi.nlm.nih.gov/32890126/)

[Xu J et al., Common pathways in neurodegenerative diseases (2020)](https://pubmed.ncbi.nlm.nih.gov/33192470/)